pulmonary%20arterial%20hypertension
PULMONARY ARTERIAL HYPERTENSION
Pulmonary arterial hypertension is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in increased pulmonary vascular resistance and ultimately leading to right heart failure.
It is a part of the spectrum of pulmonary hypertension, which is hemodynamic and pathophysiological condition defined as an increase in mean pulmonary arterial pressure ≥25 mmHg at rest.
Typical symptoms include progressive dyspnea on exertion, palpitations, fatigue, weakness, angina, syncope and abdominal distention.

Patient Education

Genetic Testing/Counseling

  • Should be offered to relatives of patients with familial pulmonary arterial hypertension (PAH), if available
  • Idiopathic pulmonary arterial hypertension (IPAH) patients should be advised regarding the availability of genetic testing & counseling for their relatives

Physical Activity

  • Physical activity to maintain adequate skeletal muscle conditioning should be limited to a symptom-free level
  • Low-level aerobic exercise (eg walking) as tolerated, is recommended
  • Heavy physical exertion or isometric exercise, exercise after meals or in extreme temp should be avoided

Travel/Altitude

  • Exposure to high altitudes may contribute to hypoxic pulmonary vasoconstriction & may not be well tolerated
  • Avoid mild degrees of hypobaric hypoxia that starts at altitude between 1500-2000 meters
  • Supplemental O2 is needed in commercial airplanes when pre-flight pulse oximetry saturation is <92%

Pregnancy

  • Pregnancy, labor, delivery & postpartum period are potentially devastating with 30-50% mortality in patients with PAH
    • Appropriate method of birth control may be used by women of childbearing potential
    • Barrier contraceptive methods & progesterone-only preparations are safe for PAH patients 
  • Pregnancy should be avoided or terminated in women with cyanotic congenital heart disease, PH & Eisenmenger syndrome
  • During menopause, hormonal therapy may be considered for intolerable menopausal symptoms in conjunction with oral anticoagulation

Psychosocial Support

  • If needed, refer patient to psychiatrist/psychologist to assist in dealing with anxiety &/or depression about their disease state
  • If available, patients & families should be referred to support groups as these are useful in improving the understanding & acceptance of the disease condition
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
15 Aug 2017
New drug applications approved by US FDA as of 1 - 15 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
04 Aug 2017
Chronic obstructive pulmonary disease (COPD) is the fourth cause of global mortality, with experts predicting a potential future rise in the prevalence rates of COPD. 
11 May 2016

In conjunction with World Asthma Day which falls on 3rd May 2016, MIMS Doctor speaks to a renowned respiratory medicine specialist, Dato' Dr. Hj Abdul Razak Abdul Muttalif, regarding the chronic airway disease.

Pearl Toh, 22 May 2016
Asthma patients on salmeterol, a long-acting beta-agonist (LABA), plus fluticasone inhaled corticosteroid (ICS) combination therapy did not have a greater risk of serious asthma-related events compared with patients receiving fluticasone alone, according to the recent AUSTRI* study.